A cerebral embolic protection device can capture and remove embolic material during transcatheter aortic-valve replacement, but whether its use lowers risk of periprocedural stroke is unknown. New research findings are summarized in a short video. https://nej.md/3CpYCQC | The New England Journal of Medicine

The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. Read the late-breaking TCT 2020 trial presented on this device - https://www.dicardiology.com/content/keystone-heart-tavr-embolic-protection-device-did-not-demonstrate-superiority #TCT2020 #TCTconnect | Diagnostic and Interventional C